Uterine Cancer
Uterine cancer encompasses endometrial carcinoma and uterine sarcoma, with molecular classification into POLE-ultramutated, MSI-H, copy-number-low, and copy-number-high (p53-abnormal) subtypes now guiding systemic therapy decisions. Advanced or recurrent disease may respond to immunotherapy in MSI-H cases or require HER2-targeted approaches in serous subtypes. CancerFax helps patients access molecular profiling and advanced treatment pathways.
- TCGA molecular subtyping, MSI & POLE profiling
- Immunotherapy, HER2-targeted & lenvatinib combinations
- Advanced uterine cancer trial & specialist access
- Key Test
- Biopsy · Imaging · Molecular Panel
- Advanced Therapies
- Targeted Therapy · Immunotherapy
- Critical Factor
- Molecular profile · Stage at diagnosis
What is Uterine Cancer
Types and Subtypes
Understanding the specific type and molecular subtype of uterine cancer is essential for determining the most appropriate treatment approach.
Symptoms and Signs
Symptoms of uterine cancer vary by stage and tumor location. Early-stage disease may be asymptomatic or cause only subtle symptoms.
Diagnosis and Staging
Definitive diagnosis requires tissue biopsy and comprehensive staging imaging. Molecular testing is essential for treatment planning.
Staging
Staging determines treatment intent and guides therapeutic decision-making.
Standard Treatment
Treatment is determined by histologic type, stage, molecular profile, and performance status.
Advanced & Emerging Therapies
The treatment landscape for advanced uterine cancer continues to evolve with new targeted agents and immunotherapy combinations.
Immunotherapy
Checkpoint Inhibitors
Pembrolizumab and nivolumab-based regimens have transformed recurrent/metastatic disease in eligible patients based on PD-L1 expression and molecular profile.
Targeted Therapy
Molecular-Guided Targeted Agents
Specific targeted agents are available for molecularly defined subgroups. Comprehensive NGS at diagnosis identifies eligible patients.
Biomarkers & Precision Medicine
Molecular biomarker testing is increasingly important for treatment selection in advanced disease.
When to Seek a Second Opinion
Specialist review is valuable at key decision points in management.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis is stage- and molecular profile-dependent.
Supportive Care
Supportive care is integral to maintaining quality of life throughout treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax supports uterine cancer patients by reviewing pathology, MMR/MSI results, HER2 testing, and staging; coordinating specialist gynecologic oncology second opinions; facilitating access to pembrolizumab-lenvatinib combinations, dostarlimab, and clinical trials; and supporting patients exploring treatment at specialist gynecologic oncology centers globally.
Get a free case reviewFrequently Asked Questions
Uterine cancer most commonly refers to endometrial carcinoma — malignancy arising from the endometrial lining of the uterus. It is the most common gynecologic cancer in developed countries and the fourth most common cancer in women in the United States.The molecular classification of endometrial cancer by The Cancer Genome Atlas (TCGA) has transformed the field: POLE ultramutated (excellent prognosis), MSI-H/dMMR (immunotherapy-responsive), copy number high/serous-like (poor prognosis), and copy... Treatment depends on stage and molecular profile. Contact CancerFax for specialist guidance.
A specialist second opinion is valuable when the diagnosis is complex, when molecular testing reveals actionable alterations, when treatment planning involves complex surgical or radiation decisions, or when disease has progressed and next-line options are being considered. Specialist centers may offer clinical trial access and treatment options not available locally.
Yes. CancerFax can assist by reviewing your medical reports, coordinating specialist second opinions, confirming molecular eligibility for targeted therapies and immunotherapy, and facilitating access to specialist centers and clinical trials globally including in China. Contact CancerFax to discuss your diagnosis and available options.